SCHEMBL2924410

SCHEMBL2924410

CCOC(=O)c1c(S(=O)(=O)N2CCN(S(=O)(=O)c3ccc(OC)cc3)CC2)c2cc(Br)ccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
MAPT P10636 1/20 0.45
GPR183 P32249 1/20 0.44
PKM P14618 4/20 0.44
CYP2C9 P11712 1/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.43
PTGDR Q13258 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
THRB P10828 1/20 0.43
HTR6 P50406 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928016 0.87 KMT2A (0.47) ALDH1A1MAPTLMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL2922661 0.86 ELANE (0.43) ALDH1A1CYP2C9PTGDRPTGDR2MEN1
SCHEMBL2929649 0.84 RAB9A (0.43) ALDH1A1PKMPOLBLMNAMEN1
SCHEMBL2345364 0.82 ELANE (0.48) ALDH1A1MAPTL3MBTL1LMNAPTGDR
SCHEMBL2345719 0.81 PTGDR (0.41) ALDH1A1MAPTL3MBTL1LMNAPTGDR
SCHEMBL2348486 0.81 USP2 (0.43) PTGDRPTGDR2HTR6HTTSMN1; SMN2
SCHEMBL2351720 0.80 HTR6 (0.42) ALDH1A1MAPTLMNAPTGDRPTGDR2
SCHEMBL2343252 0.79 HTR6 (0.50) MAPTPOLBL3MBTL1PTGDRPTGDR2
SCHEMBL2924748 0.79 ACLY (0.45) ALDH1A1MAPTMEN1KMT2AHTR6
SCHEMBL2345691 0.79 HTR6 (0.39) ALDH1A1MAPTL3MBTL1LMNAPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534695-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2010-09-29 EP disclosed
US-20090186871-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2009-07-23 US disclosed
US-7560546-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-07-14 US disclosed
EP-1534695-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2008-06-11 EP disclosed
US-20050261496-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2005-11-24 US disclosed
EP-1534695-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2005-06-01 EP disclosed
WO-2004014851-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261496-A1 Tyrosine kinase inhibitors ABL1, JAK2, ERBB2 ALDH1A1 2434/4885MAPT 2505/4885GPR183 459/4885
US-20090186871-A1 Tyrosine kinase inhibitors ABL1, JAK2, ERBB2 ALDH1A1 2434/4885MAPT 2505/4885GPR183 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.